Stock listing

Frankfurt:AX9 Akebia Therapeutics, Inc. Aktie

German listing (Frankfurt) of Akebia Therapeutics, Inc. · home listing NASDAQ:AKBA

Follow Akebia Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:AX9

€0.507 EUR +0.012 (+2.5%)

Close on Oct 26, 2026

Day range
€0.507 – €0.507 EUROct 26, 2026
Market cap
€140.4M EURAt the close on Oct 26, 2026 · price × 277.1M shares outstanding
Akebia Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AKBA · Home$0.707 USD-0.036 (-4.8%)2,771,081$0.721$0.735$0.695$0.742Close on Oct 30, 2026
Frankfurt:AX9€0.507 EUR+0.012 (+2.5%)—€0.507€0.507€0.507€0.494Close on Oct 26, 2026
Ticker
Frankfurt:AX9
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Akebia Therapeutics (NASDAQ:AKBA) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 8:00 AM ET

    Register

Replays

  • Akebia Therapeutics (NASDAQ:AKBA) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Akebia Therapeutics (NASDAQ:AKBA) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

  • Akebia Therapeutics (NASDAQ:AKBA) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

Oct 29, 2026

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

Oct 26, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Oct 7, 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Oct 6, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Sep 14, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Sep 1, 2026

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 5, 2026

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Aug 3, 2026

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Jul 29, 2026

All Akebia Therapeutics, Inc. news

Decks

Akebia Therapeutics, Inc. on 6ix

News releases
31 in the last 12 months · 183 in all · newest Oct 29, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Aug 5, 2026
Decks
18 decks · latest Apr 2, 2026

Where Akebia Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AKBA · Home listingNASDAQUnited StatesUSD
Tradegate:AX9TradegateGermanyEUR
LS Exchange:A1XF0SLS ExchangeGermanyEUR
BOATS:AKBABOATSUnited StatesUSD
Lang & Schwarz:A1XF0SLang & SchwarzGermanyEUR
gettex:AX9gettexGermanyEUR
Hamburg:AX9HamburgGermanyEUR
BX Swiss:AX9BX SwissSwitzerlandCHF
Dusseldorf:AX9DusseldorfGermanyEUR
Frankfurt:AX9 · This pageFrankfurtGermanyEUR
Munich:AX9MunichGermanyEUR
Stuttgart:AX9StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Akebia Therapeutics, Inc.